Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | F9 | P00740 | 3/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.30 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31067185 | 1.00 | SLC6A4 (0.33) | SLC6A4SLC6A3SLC6A2PSEN1PSEN2 | |
| SCHEMBL31067131 | 1.00 | SLC6A4 (0.33) | SLC6A4SLC6A3SLC6A2PSEN1PSEN2 | |
| SCHEMBL31067153 | 0.84 | C5AR1 (0.34) | — | |
| SCHEMBL31067167 | 0.84 | C5AR1 (0.34) | — | |
| SCHEMBL31067189 | 0.84 | C5AR1 (0.34) | — | |
| Ammonia Solution, Strong SCHEMBL28903694 | 0.70 | KDM1A (0.48) | SLC6A4SLC6A3SLC6A2PSEN1PSEN2 | |
| SCHEMBL17033038 | 0.68 | KDM1A (0.50) | SLC6A4SLC6A3SLC6A2PSEN1PSEN2 | |
| SCHEMBL31067218 | 0.67 | MEN1 (0.43) | SLC6A4SLC6A3SLC6A2PSEN1PSEN2 | |
| SCHEMBL31067231 | 0.66 | PARP1 (0.36) | SLC6A4SLC6A3SLC6A2KDM1AF9 | |
| SCHEMBL257282 | 0.66 | SLC6A4 (0.50) | SLC6A4SLC6A3SLC6A2PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026047575-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2026-03-05 | — | — | WO | disclosed |
| EP-4673431-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | Novartis AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| US-12129246-B1 | Hydroquinazoline derivatives for the treatment of a disease or disorder | NOVARTIS AG (CH) | 2024-10-29 | — | — | US | disclosed |
| US-20240336598-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-10-10 | — | — | US | disclosed |
| WO-2024180499-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2024-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129246-B1 | Hydroquinazoline derivatives for the treatment of a disease or disorder | RECQL, NRAS, RAB1A | SLC6A4 617/4885SLC6A3 162/4885SLC6A2 201/4885 |
| US-20240336598-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | RECQL, NRAS, RAB1A | SLC6A4 617/4885SLC6A3 162/4885SLC6A2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.